Related Experiment Videos

Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study

Boris L G van Wijk1, Jerry Avorn, Daniel H Solomon

  • 1Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. b.l.g.vanwijk@pharm.uu.nl

Journal of Hypertension
|February 7, 2007
PubMed

Insights

Many patients stop blood pressure medication but most restart therapy. Hospitalization for cardiovascular disease or refilling other heart medications increases the likelihood of restarting antihypertensive drugs.

Area of Science:

  • Cardiovascular medicine
  • Pharmacology
  • Public health

Background:

  • Many patients discontinue blood pressure-lowering medication for extended periods.
  • Understanding reinitiation patterns is crucial for managing hypertension.
  • Prolonged discontinuation may impact long-term cardiovascular health outcomes.

Purpose of the Study:

  • To assess patterns of restarting antihypertensive drugs after prolonged discontinuation.
  • To identify factors associated with reinitiating blood pressure-lowering treatment.
  • To inform clinical awareness regarding medication adherence in hypertensive patients.

Main Methods:

  • Retrospective cohort study using the PHARMO database in The Netherlands.
  • Inclusion of new users of blood pressure-lowering medication with at least 180 days of discontinuation.
  • Multivariable Cox proportional hazard and case-crossover analyses were employed.

Main Results:

  • Over 51% of patients discontinued blood pressure-lowering treatment, with 19.3% restarting within 1 year and 60.7% within 6 years.
  • Each additional year on therapy increased the likelihood of restarting (OR = 1.38).
  • Hospitalization for cardiovascular disease (OR = 2.20) and refilling other cardiovascular medications (OR = 1.25) were associated with reinitiation.

Conclusions:

  • A significant proportion of patients restart antihypertensive drugs after discontinuation.
  • Cardiovascular events and concomitant cardiovascular medication use influence treatment reinitiation.
  • Discontinuation decisions may be drug-specific rather than a general non-adherence behavior.
Abstract

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...